Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
复制标题
DOI：
10.1080/21645515.2018.1442162
复制
发表时间：
2018-01-01
影响因子：
4.8
通讯作者：
Bastidas, Adriana
中科院分区：
文献类型：
--
作者：
Schwarz, Tino F.;Volpe, Stephanie;Bastidas, Adriana
背景资料：在60岁的成年人中，两剂带状疱疹亚单位疫苗（HZ/su; 50 μ g水痘-带状疱疹病毒糖蛋白E [gE]和AS 01（B）佐剂系统）引起的体液和细胞介导的免疫应答持续至少6年。我们评估了免疫原性九年后初始vaccination.Methods：这个开放的扩展研究（NCT 02735915），随后70名参与者谁收到两个HZ/su剂量在初始试验（NCT 00434577）。血液样本，以评估细胞（细胞内细胞因子染色）和体液（ELISA）免疫接种后9年首次vaccination.Results：参与者的平均年龄在剂量1是72.3岁。从第1次给药后第4年至第9年，表达2种活化标志物的gE特异性CD 4 + T细胞的平均频率相对于接种前增加了倍数。从第4年开始，抗gE抗体几何平均浓度趋于稳定，并保持高于接种前水平。各年龄层（60-69岁，70岁）第9年的免疫原性相似，并使用长达6年的数据证实了统计预测模型结果。使用截至第9年的所有数据进一步建模，预测免疫反应将保持在疫苗接种前水平以上，直至第15年。结论：在60岁的成年人中，HZ/su诱导的免疫原性在初始疫苗接种后至少9年内保持在疫苗接种前水平以上。总结：接种HZ/su后，无论年龄组如何，细胞介导和体液免疫均保持高于接种前水平，直至9岁。预计免疫应答在初次接种后15年内仍高于基线。
Background: In adults aged 60years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 mu g varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post-initial vaccination.Methods: This open extension study (NCT02735915) followed 70 participants who received two HZ/su doses in the initial trial (NCT00434577). Blood samples to assess the cellular (intracellular cytokine staining) and humoral (ELISA) immunity were taken at year nine post-initial vaccination.Results: Participants' mean age at dose 1 was 72.3years. The fold increases over pre-vaccination in the mean frequency of gE-specific CD4+ T-cells expressing 2 activation markers plateaued from year four post-dose 1 until year nine. Anti-gE antibody geometric mean concentrations plateaued and remained above pre-vaccination levels from year four onwards. Immunogenicity at year nine was similar across age strata (60-69, 70years) and confirmed statistical prediction model results using data for up to year six. Further modeling using all data up to year nine predicted immune responses would remain above the pre-vaccination level up to year 15.Conclusion: In adults aged 60years, HZ/su-induced immunogenicity remained above pre-vaccination levels for at least nine years post-initial vaccination.Summary: After vaccination with HZ/su, both cell mediated and humoral immunity remained above pre-vaccination levels up to year 9 regardless of age group. Immune responses are predicted to remain above baseline up to 15years post initial vaccination.